• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » diaDexus highlights findings of two PLAC Lp-PLA(2) activity studies

diaDexus highlights findings of two PLAC Lp-PLA(2) activity studies

March 19, 2012
CenterWatch Staff

San Francisco–based diaDexus, a company focused on proprietary cardiovascular diagnostic products, reported highlights from two recent studies evaluating the clinical utility of its PLACR Test for Lp-PLA(2) activity.

The PLACR Test for Lp-PLA(2) activity measures the pro-inflammatory enzymatic activity of Lp-PLA(2), and is CE-marked for use outside the U.S. and is an investigational assay in the U.S. The test was used to examine patient samples from two well-known clinical studies of statins, LIPID and JUPITER.

The LIPID trial was a randomized controlled trial to determine the effects of cholesterol lowering on death from coronary heart disease among patients with coronary disease and average lipid levels. The analyses of the trial indicate that a reduction in Lp-PLA(2) levels may impact coronary heart disease outcomes more than a reduction in LDL cholesterol in response to statin therapy.

“The LIPID trial found that the more you lower Lp-PLA(2), the more you reduce the risk of coronary heart disease,” said Brian E. Ward, Ph.D., CEO, diaDexus. “This is compelling because Lp-PLA(2) levels have not been measured this way in prior studies.

The JUPITER trial was a randomized, double-blind, placebo-controlled study that investigated whether rosuvastatin 20mg compared to a placebo would decrease the rate of first major cardiovascular events. The trial demonstrated that Lp-PLA(2) levels are predictive of cardiovascular events in apparently healthy men and women. Additionally, JUPITER showed a positive trend between lower Lp-PLA(2) levels and cardiovascular outcomes as a response to statins.

“Taken together, the LIPID and JUPITER analyses performed by our PLACR Test for Lp-PLA(2) activity should be of great interest to physicians, their patients and advisory bodies, especially as they understand the differences in the two study populations,” added Ward.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing